Search Results
Oct 02, 2025, 17:31 ET Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight
Available pharmacological interventions include glucocorticoids, mycophenolate, rituximab, tocilizumab, teprotumumab, and cyclosporine/mTOR inhibitors. Oral prednisone is commonly used, while higher doses or intravenous administration are typically reserved for cases involving optic nerve
More news about: DelveInsight Business Research, LLP
Oct 02, 2025, 08:30 ET Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
expanded access case in triple-negative breast cancer (TNBC) treated with a combination regimen that included the Company's investigational pan-PI3K/mTOR inhibitor, paxalisib. After three weeks of combination immunotherapy/chemotherapy plus paxalisib, imaging performed at the treating institution showed
More news about: Kazia Therapeutics Limited
Oct 01, 2025, 09:21 ET Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). Kazia will provide its investigational drug paxalisib, a brain-penetrant, dual PI3K/mTOR inhibitor, to support the study. Project Overview DMG/DIPG represents one of the most devastating pediatric cancers, accounting
More news about: Kazia Therapeutics Limited
Sep 11, 2025, 08:00 ET Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia's investigational PI3K–mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a statistically significant reduction in single circulating tumor cells and achieved
More news about: Kazia Therapeutics Limited